Schlichter Kadosh, Y.; Goorevitch, N.; Teralı, K.; Gopas, J.; Kushmaro, A.
Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases Pseudomonas aeruginosa Tolerance to Ciprofloxacin. Pharmaceuticals 2024, 17, 1472.
https://doi.org/10.3390/ph17111472
AMA Style
Schlichter Kadosh Y, Goorevitch N, Teralı K, Gopas J, Kushmaro A.
Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases Pseudomonas aeruginosa Tolerance to Ciprofloxacin. Pharmaceuticals. 2024; 17(11):1472.
https://doi.org/10.3390/ph17111472
Chicago/Turabian Style
Schlichter Kadosh, Yael, Noa Goorevitch, Kerem Teralı, Jacob Gopas, and Ariel Kushmaro.
2024. "Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases Pseudomonas aeruginosa Tolerance to Ciprofloxacin" Pharmaceuticals 17, no. 11: 1472.
https://doi.org/10.3390/ph17111472
APA Style
Schlichter Kadosh, Y., Goorevitch, N., Teralı, K., Gopas, J., & Kushmaro, A.
(2024). Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases Pseudomonas aeruginosa Tolerance to Ciprofloxacin. Pharmaceuticals, 17(11), 1472.
https://doi.org/10.3390/ph17111472
